• Founded: 2017
  • Location: Boston, MA
  • Employee range: 50 - 200
  • Clinical stage: Clin2
  • Therapy area: Seborrheic keratosis
  • Drug types: DRM
  • Lead product: SM-020
  • Product link:
  • Funding: $28M A Dec 2021; $8M A Jun 2019

job board

Short description:

Topical Bacterial Products

Drug notes:

SM-030 Clin2 photodamage hyperpigmentation

Long description:

DermBiont is a dermatology company developing therapeutics to treat and prevent skin diseases. Important to healthy skin is the dermal microbiome which includes millions of bacteria, fungi and viruses. DermBiont is developing targeted small molecule therapeutics (pre-, pro- and post-biotics) that can repair dysbiosis of the microbiome. The current pipeline includes small molecules in phase 2 clinical trials for dermatitis, keratoses and photodamage hyperpigmentation. DermBiont’s therapeutics are topical and address the root cause of the skin diseases.


Vice President of Clinical Operations
6425 Christie Avenue, Emeryville, CA|15 days ago
Associate Director or Director of Regulatory Affai...
6425 Christie Avenue, Emeryville, CA|74 days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy